Literature DB >> 17950881

Cancer clinical trials: development and implementation.

David M Vail1.   

Abstract

Although much of the current standard of care in veterinary oncology is based on retrospective studies or transference from the human literature, a new era of clinical trial awareness brought on by new consortia and cooperative investigative groups is beginning to change this limitation. The use of controlled, randomized, blind multicenter trials testing new cytotoxics and cytostatic agents is now becoming the norm rather than the exception. Ultimately, advanced clinical trial design applied to companion animal populations should advance veterinary-based practice and inform future human clinical trials that may follow.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950881     DOI: 10.1016/j.cvsm.2007.06.007

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  10 in total

1.  Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

Authors:  C Robat; C London; L Bunting; L McCartan; N Stingle; K Selting; I Kurzman; D M Vail
Journal:  Vet Comp Oncol       Date:  2011-01-31       Impact factor: 2.613

2.  Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Authors:  R Mani; R Yan; X Mo; C-S Chen; M A Phelps; R Klisovic; J C Byrd; W C Kisseberth; C A London; N Muthusamy
Journal:  Vet Comp Oncol       Date:  2016-05-02       Impact factor: 2.613

3.  In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers.

Authors:  Sita S Withers; Daniel York; Eric Johnson; Sami Al-Nadaf; Katherine A Skorupski; Carlos O Rodriguez; Jenna H Burton; Teri Guerrero; Kriste Sein; Luke Wittenburg; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2018-08-08       Impact factor: 2.613

4.  An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.

Authors:  L Marconato; R Finotello; U Bonfanti; M Dacasto; L Beatrice; S Pizzoni; V F Leone; G Balestra; T Furlanello; C Rohrer Bley; L Aresu
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

5.  Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.

Authors:  J H Burton; R O Venable; D M Vail; L E Williams; C A Clifford; S M Axiak-Bechtel; A C Avery; D H Thamm
Journal:  J Vet Intern Med       Date:  2015-06-25       Impact factor: 3.333

Review 6.  Canine cancer immunotherapy studies: linking mouse and human.

Authors:  Jiwon S Park; Sita S Withers; Jaime F Modiano; Michael S Kent; Mingyi Chen; Jesus I Luna; William T N Culp; Ellen E Sparger; Robert B Rebhun; Arta M Monjazeb; William J Murphy; Robert J Canter
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

7.  Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.

Authors:  Q Fournier; J-C Serra; I Handel; J Lawrence
Journal:  J Vet Intern Med       Date:  2017-12-04       Impact factor: 3.333

8.  Phase I dose-escalation study of nimustine in tumor-bearing dogs.

Authors:  Masashi Takahashi; Yuko Goto-Koshino; Kenjiro Fukushima; Hideyuki Kanemoto; Ko Nakashima; Yasuhito Fujino; Koichi Ohno; Yasuyuki Endo; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2014-02-10       Impact factor: 1.267

9.  Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI.

Authors:  G Segev; J E Sykes; D J Klumpp; A J Schaeffer; E M Antaki; B A Byrne; R E Yaggie; J L Westropp
Journal:  J Vet Intern Med       Date:  2017-12-15       Impact factor: 3.333

10.  Regenerative collagen biomembrane: Interim results of a Phase I veterinary clinical trial for skin repair.

Authors:  Andreas Kaasi; João F Lima-Neto; José A Matiello-Filho; Mário H S Calejo; André L Jardini; Paulo Kharmandayan
Journal:  F1000Res       Date:  2018-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.